

Single Day Event

Xiaoyi Niu, *Jiangsu Hengrui Pharmaceuticals CO., LTD*
Haiqiang Luo, *Jiangsu Hengrui Pharmaceuticals CO., LTD*


Automatic Generation of Multilingual Data Reviewer's Guide (DRG) in NDA Submission



Disclaimer

The views and opinions expressed in this presentation are those of the authors and do not necessarily reflect the official policy or position of Hengrui Pharmaceuticals (恒瑞) .

Contents





What is a Data Reviewer's Guide?

• Structure

Clinical Study Data Reviewer's Guide

Analysis Data Reviewer's Guide

cSDRG	Contents	ADRG	Contents
① Introduction	1. Introduction.....4	① Introduction	1. Introduction.....4
② Protocol Description	1.1 Purpose.....4	② Protocol Description	1.1 Purpose.....4
	1.2 Acronyms.....4		1.2 Acronyms.....4
	1.3 Study Data Standards and Dictionary Inventory.....4		1.3 Study Data Standards and Dictionary Inventory.....4
	1.4 Source Data Used for Analysis Dataset Creation.....4		1.4 Source Data Used for Analysis Dataset Creation.....4
	2. Protocol Description.....4		2. Protocol Description.....4
	2.1 Protocol Number and Title.....4		2.1 Protocol Number and Title.....4
	2.2 Protocol Design.....4		2.2 Protocol Design in Relation to ADaM Concepts.....4
	2.3 Trial Design Datasets.....4		3. Analysis Considerations Related to Multiple Analysis Datasets.....4
	2.3.1 TA – Trial Arms.....4		3.1 Overview.....4
	2.3.2 TE – Trial Elements.....4		3.2 Treatment Variables.....4
	2.3.3 TV – Trial Visits.....4		3.3 Analysis Considerations Related to Multiple Analysis Datasets.....4
	2.3.4 TI – Trial Inclusion/Exclusion Criteria.....4		3.4 Imputation/Derivation Methods.....4
	2.3.5 TS – Trial Summary.....4		4. Analysis Data Creation and Processing Issues.....4
	3. Data Description.....4		4.1 Split Datasets.....4
	3.1 Overview.....4		4.2 Data Dependencies.....4
	3.2 Data Flow Diagram.....4		4.3 Intermediate Datasets.....4
	3.3 Data Description.....4		5. Analysis Dataset Descriptions.....4
	3.4 Data Description.....4		5.1 Overview.....4
	3.5 Data Description.....4		5.2 Analysis Dataset Descriptions.....4
	3.6 Data Description.....4		5.2.1 ADaM – Subject Level Analysis Dataset.....4
	3.7 Data Description.....4		5.2.2 ADaM – Dataset – Dataset Label.....4
	3.8 Data Description.....4		6. Data Conformance Summary.....4
	3.9 Data Description.....4		6.1 Conformance Issues.....4
	3.10 Data Description.....4		6.2 Issues Summary.....4
	3.11 Data Description.....4		7. Submission of Programs.....4
	3.12 Data Description.....4		7.1 ADaM Programs.....4
	3.13 Data Description.....4		7.2 Analysis Programs.....4
	3.14 Data Description.....4		7.3 Macro Programs.....4
	3.15 Data Description.....4		8. Appendix.....4
	3.16 Data Description.....4		8.1 Legacy Data Conversion Plan and Report Appendix.....4
	3.17 Data Description.....4		8.2 Conversion Data Flow.....4
	3.18 Data Description.....4		8.3 Converted Data Summary.....4
	3.19 Data Description.....4		8.4 Issue Encountered and Resolved.....4
	3.20 Data Description.....4		8.5 Tracking Data Flow.....4
	3.21 Data Description.....4		8.6 Outstanding Issues.....4
	3.22 Data Description.....4		
	3.23 Data Description.....4		
	3.24 Data Description.....4		
	3.25 Data Description.....4		
	3.26 Data Description.....4		
	3.27 Data Description.....4		
	3.28 Data Description.....4		
	3.29 Data Description.....4		
	3.30 Data Description.....4		
	3.31 Data Description.....4		
	3.32 Data Description.....4		
	3.33 Data Description.....4		
	3.34 Data Description.....4		
	3.35 Data Description.....4		
	3.36 Data Description.....4		
	3.37 Data Description.....4		
	3.38 Data Description.....4		
	3.39 Data Description.....4		
	3.40 Data Description.....4		
	3.41 Data Description.....4		
	3.42 Data Description.....4		
	3.43 Data Description.....4		
	3.44 Data Description.....4		
	3.45 Data Description.....4		
	3.46 Data Description.....4		
	3.47 Data Description.....4		
	3.48 Data Description.....4		
	3.49 Data Description.....4		
	3.50 Data Description.....4		
	3.51 Data Description.....4		
	3.52 Data Description.....4		
	3.53 Data Description.....4		
	3.54 Data Description.....4		
	3.55 Data Description.....4		
	3.56 Data Description.....4		
	3.57 Data Description.....4		
	3.58 Data Description.....4		
	3.59 Data Description.....4		
	3.60 Data Description.....4		
	3.61 Data Description.....4		
	3.62 Data Description.....4		
	3.63 Data Description.....4		
	3.64 Data Description.....4		
	3.65 Data Description.....4		
	3.66 Data Description.....4		
	3.67 Data Description.....4		
	3.68 Data Description.....4		
	3.69 Data Description.....4		
	3.70 Data Description.....4		
	3.71 Data Description.....4		
	3.72 Data Description.....4		
	3.73 Data Description.....4		
	3.74 Data Description.....4		
	3.75 Data Description.....4		
	3.76 Data Description.....4		
	3.77 Data Description.....4		
	3.78 Data Description.....4		
	3.79 Data Description.....4		
	3.80 Data Description.....4		
	3.81 Data Description.....4		
	3.82 Data Description.....4		
	3.83 Data Description.....4		
	3.84 Data Description.....4		
	3.85 Data Description.....4		
	3.86 Data Description.....4		
	3.87 Data Description.....4		
	3.88 Data Description.....4		
	3.89 Data Description.....4		
	3.90 Data Description.....4		
	3.91 Data Description.....4		
	3.92 Data Description.....4		
	3.93 Data Description.....4		
	3.94 Data Description.....4		
	3.95 Data Description.....4		
	3.96 Data Description.....4		
	3.97 Data Description.....4		
	3.98 Data Description.....4		
	3.99 Data Description.....4		
	3.100 Data Description.....4		



Why

KEY: Y = yes (included), N = no (not included), O = optionally included

Topic	Description	define.xml [†]	cSDRG	ADRG
Protocol Information	Summary of protocol number, title, and design.	Y	Y	Y
Trial Design Data	Information pertaining to trial design datasets.	Y	Y	O
Acronyms	List of sponsor-specific acronyms.	N	Y	Y
Standards Versions	Summary of standards used for data and metadata.	Y	Y	
Dictionary Versions	Summary of external dictionaries used.			
Annotated CRFs	Summary of annotated CRFs.			
Study Data Overview	A high level summary of study data.			
Trial Design Data	Information pertaining to trial design datasets.			
Dataset Metadata	Summary of dataset description.			
Variable Metadata	Summary of variable description.			
Value-Level Metadata	Summary of value-level description.			
CodeLists/Controlled Terminology	Summary of code lists and controlled terminology.			
Computational Algorithms	Summary of computational algorithms.			
Comments	Not applicable.			
Analysis Results Metadata	Information pertaining to analysis results metadata.			
Analysis Considerations	Summary of analysis considerations.			
Conformance / Compliance Findings	Summary of conformance checks and compliance findings.			
Legacy data conversion	Describes conversion to standard format.			

- *It's hard to keep consistency in both template structure and contents during translation.*
- *DRG preparation process is time-consuming, laborious, and error-prone.*

- To tell the story
- To discuss the challenges


* Note that there are separate define.xml files provided to describe the data collection and the tabulation data should reside in the SDTM (define.xml), and the analysis results should reside in the ADaM (define.xml).

** Note that the tabulation define.xml contains links to the annotated CRFs.


Automatic Generation of SDRG – SDRG Dissection



Automatic Generation of SDRG – SDRG Dissection



Automatic Generation of SDRG – Re2Go Flowchart





Automatic Generation of SDRG – Re2Go User-Interface

Re2Go (An Automation Tool for Generating Reviewer's Guide) ×

Input #0(Required): Reviewer's Guide Setting

RG's Type: ☒ SDTM ☐ ADaM

RG's Template File: **Browse** **Clear Highlights**

Template's Version:

Input #1(expected): Protocol Information

Protocol Word File: **Browse**

Sponsor Name >>>>

Protocol Number >>> <<<< Extract Protocol Information

Protocol Version >>

Protocol Title >>>

Protocol Design >>> ☐ IE Criteria >>> ☐ Protocol Acronyms >>> ☐

Clear All

Input #2(Required): Re2Go Excel Data File

Browse

Input #3(expected): Pinnacle 21 Report File

Browse

 **Press me to start >>>>**

aCRF
(pdf)



SDRG EN Template

This is where you perform manual modification.

You may delete this note.

Study <Protocol Number> Clinical Study Data Reviewer's Guide

• Introduction

• 1.1 Purpose

This document provides context for tabulation datasets and terminology that benefit from additional explanation beyond the Data Definitions document (define.xml).

• 1.2 Acronyms

<Protocol Acronyms>

Acronym	Translation

• 1.3 Study Data Standards and Dictionary Inventory

Standards	Standards Used
SDTM	SDTM V1.7 / SDTMIG V3.3
Controlled Terminology	CDISC SDTM CT 2021-06-25
Data Definitions	Define.xml v2.1
Medications Dictionary	WHO Drug Version GLOBAL B3Mar19
Medical Events Dictionary	MedDRA v24.0
TAUG (if applicable)	
Other standards (optional)	

• 2. Protocol Description

• 2.1 Protocol Number and Title

Protocol Number: <Protocol Number>

Protocol Title: <Protocol Title>

Protocol Versions: <Protocol Versions>

(Note here changes in protocol amendments that affected data collection or interpretation).

• 2.2 Protocol Design

<Protocol Design>

This is where the automation process occurs.

SDRG EN Template

This is where the automation process occurs.

This is where you perform manual modification.

You may delete this note.

2.3 Trial Design Datasets

Are Trial Design datasets included in the submission? **Yes**

2.3.1 TA – Trial Arms

The study consists of **3** treatment group, ie. ARM(ARMCD): **PBO (Placebo), A (Drug A), B (Drug B)**.

2.3.2 TE – Trial Elements

The study consists of **6** elements: **Screen, Run-In, Placebo, Drug A, Drug B, Follow-Up**.

2.3.3 TV – Trial Visits

Trial Visits domain is only included the planned visit. Those unscheduled visits are not included in this domain.

2.3.4 TI – Trial Inclusion/Exclusion Criteria

The trial inclusion/exclusion criteria are not fully described in the TI domain. Please refer to [Appendix I: Inclusion/Exclusion Criteria](#) for the full text of the criteria.

2.3.5 TS – Trial Summary

The TS domain contains **35** parameters including study title, study design, study purpose, etc.

3. Subject Data Description

3.1 Overview

Are the submitted data taken from an ongoing study? **Yes**

If yes, describe the data cut or database status:

(Text here)

Were the SDTM datasets used as sources for the analysis datasets? **Yes**

If no, what were the sources of analysis datasets?

(Text here)

Do the submission datasets include screen failures? **Yes**

If yes, which datasets include screen failure data?

AE, CM, CV, DS, EG, IE, LB, MH, PE, PR, QS, RE, SE, SU, SV, VS

Were any domains planned, but not submitted because no data were collected? **Yes**

If yes, list domains not submitted:

NR



SDRG EN Template

This is where the automation process occurs.

This is where you perform manual modification.

You may delete this note.

3.4 SDTM Subject Domains¹

Dataset – Dataset Label	Efficacy	Safety	Other	Custom	SUPP	Related Using RELREC

4. Data Conformance Summary¹

4.1 Conformance Inputs¹

- Was a validator used to evaluate conformance? **<P21_YN>**
 - If yes, specify the version(s) of the validation rules:
<P21_VERNRULE>
- Were sponsor-defined validation rules used to evaluate conformance? **No**
 - If yes, describe any significant sponsor-defined validation rules:
(Text or table here. If significant amount, include as an appendix).
- Were the SDTM datasets evaluated in relation to define.xml? **<CHECK_WITH_DEFINE_YN>**
- Was define.xml evaluated? **Yes**
- Provide any additional compliance evaluation information:
(Text here).

4.2 Issues Summary¹

Dataset	Diagnostic Message	Severity	Count	Explanation

4.3 Additional Conformance Details¹

(Complete table below or indicate this section is not applicable).

Dataset	Diagnostic Message	Severity	Count	Explanation

Appendix I: Inclusion/Exclusion Criteria¹

Protocol/ Amendment Version	Category	IETESTCD	Full Text of Criterion



SDTM/ADaM Construct Excel Data File (SAS Macro)

For Section 2.3 Trial Design Datasets

Re2Go Excel Data - EN.xlsx - Excel

文件 开始 插入 页面布局 公式 数据 审阅 视图 开发工具

粘贴 剪贴板 字体 对齐方式 数字

C3 : Screen, Run-In, Placebo, Drug A, Drug B, Follow-Up

	A	B	C	D
1	Domain	Count	List	
2	TA	3	PBO (Placebo), A (Drug A), B (Drug B)	
3	TE	6	Screen, Run-In, Placebo, Drug A, Drug B, Follow-Up	
4	TS	35		
5	TDM	Yes		
6				
7				
8				
9				

Trial_Design Subject_Domain SUPPAE SUPPCM ...



SDTM/ADaM Construct Excel Data File (SAS Macro)

For Section 3. Subject Data Description

	A	B	C	D	E	F	G	H	I
	Dataset - Dataset Label	Efficac	Safet	Othe	Custor	SUPF	Related Using RELRE	Screen Failure Data?	Null Dataset
1	AE - Adverse Events		X			X		X	
2	CM - Concomitant/Prior Medications		X			X		X	
3	CO - Comments			X					
4	CV - Cardiovascular System Findings			X				X	
5	DM - Demographics			X		X			
6	DS - Disposition			X		X		X	
7	DV - Protocol Deviations			X		X			
8	EC - Exposure as Collected			X					
9	EG - ECG Test Results		X			X		X	
10	EX - Exposure			X		X			
11	IE - Inclusion/Exclusion Criteria Not Met			X				X	
12	LB - Laboratory Test Results		X			X		X	
13	MB - Microbiology Specimen			X					
14	MH - Medical History			X		X		X	
15	MI - Microscopic Findings			X					
16	PE - Physical Examination		X					X	
17	PR - Procedures			X		X		X	
18	QS - Questionnaires		X					X	
19	RE - Respiratory System Findings		X					X	
20	RS - Disease Response and Clin Classification	X					TR		
21	SE - Subject Elements			X				X	
22	SS - Subject Status		X						
23	SU - Substance Use			X				X	
24	SV - Subject Visits			X				X	
25	TR - Tumor/Lesion Results	X				X	TU, RS		
26	TU - Tumor/Lesion Identification	X				X	TR		
27	VS - Vital Signs		X					X	
28	XJ - Genetic Mutations			X	X				
29	XR - Pregnancy Report			X	X				X
30									
31									

	A	B
1	QNAM	Description
2	AEACNKB	Action Taken with Carboplatin
3	AEACNYT	Action Taken with Etoposide
4	AECMNO	Related CM ID
5	AECOM	AE Note
6	AEDIS	Leading to Discontinue
7	AEHORMYN	Hormone Treatments for irAE YN?
8	AEIRAEYN	irAE YN?
9	AEPRIOR	Prior AE?
10	AERELKB	Causality with Carboplatin
11	AERELYT	Causality with Etoposide
12	AESIEYN	Special AE?
13	AESOURCE	AE Source
14	DICTVER	Dictionary Version
15	FENRLOBS	Records from First Enrollment (Y/null)
16	IRAECAT	irAE Cluster
17	IRAESCAT	irAE Sub-cluster
18	LABAE	Related Lab
19		

Subject_Domain SUPPAE SUPPCM



Automatic Generation of SDRG

Re2G

Re2Go (An Automation Tool for Generating Reviewer's Guide)



Input #0(Required): Reviewer's Guide Setting

RG's Type: ☒ SDTM ☐ ADaM

RG's Template File:

Browse

Clear
Highlights

Template's Version:



Input #1(expected): Protocol Information

Protocol Word File:

Browse

Sponsor Name >>>>>

Protocol Number >>>

Protocol Version >>

Protocol Title >>>>

Protocol Design >>>



IE Criteria >>>



Protocol Acronyms >>>



<<<< Extract Protocol Information

Clear
All

Input #2(Required): Re2Go Excel Data File

Browse

Input #3(expected): Pinnacle 21 Report File

Browse



Press me to start >>>>>

Show Re2Go UI



Re2Go Output

- ✓ Sponsor Name
- ✓ Acronym
- ✓ Protocol Number, Title, Version, Design
- ✓ Information of Trial Design Datasets (eg. TA, TE, TS)
- ✓ Information of Subject Datasets (eg. Screen Failure, Null Datasets, SUPP-)
- ✓ Data Conformance Summary (Validator, Issues)
- ✓ Inclusion/Exclusion Criteria

Clinical Study Data Reviewer's Guide

Big Pharma

Study Re2Go-I-101

cSDRG Template Version 2019-07-10



Automatic Generation of ADRG

ADRG

- ① Introduction
- ② Protocol Description
- ③ Analysis Considerations Related to Multiple Analysis Datasets
- ④ Analysis Data Creation and Processing Issues
- ⑤ Analysis Dataset Descriptions
- ⑥ Data Conformance Summary
- ⑦ Submission of Programs
- ⑧ Appendix; Legacy Data

1.2 Acronyms

Protocol Acronyms

Acronym	Translation
aCRF	Annotated Case Report Form
ADaM	Analysis Dataset Model
ADRG	Analysis Data Reviewer's Guide
eCRF	
eDT	
IG	
NA	
SDTM	

2. Protocol Description

2.1 Protocol Number and Title

Protocol Number: <Protocol Number>

Protocol Title: <Protocol Title>

5.2 Analysis Datasets

Dataset Dataset Label	Class	Efficacy	Safety	Baseline or other subject characteristics	PK/PD	Primary Objective	Structure
ADSL							
Subject Level Analysis Dataset							

action or interpretation)

6.2 Issues Summary


Dataset	Diagnostic Message	Severity	Count	Explanation

Preparing Multilingual SDRG - Flowchart



临床研究数据 审阅说明

Advantages of Using Re2Go

- 
- ✓ Only four input sources:
 - a) *DRG Template*
 - b) *Study Protocol*
 - Information directedly extracted from protocol (e.g. study design, inclusion/exclusion criteria) is more accurate.
 - c) *SDTM/ADaM Datasets*
 - Key dataset information can be matched to the corresponding sections.
 - d) *Pinnacle 21 Report*
 - ✓ Automatically identifying DRG language while reading in template
 - ✓ Efficient operating process
 - ✓ Updating DRG with ease in response to new release of template

Q & A

Thank You!

联系方式(Contact) :

牛潇亿 (Xiaoyi Niu): Xiaoyi.Niu@hengrui.com

罗海强 (Haiqiang Luo): Haiqiang.Luo@hengrui.com



**The Global Healthcare
Data Science Community**

Contact Channels

📞 UK +44 1843 609600
📞 USA +1 609 514 5105
✉️ office@phuse.global
🌐 phuse.global

Social Media

🐦 [@phusetwitta](https://twitter.com/phusetwitta)
📘 [/phusebook](https://facebook.com/phusebook)
▶️ [/phusetube](https://youtube.com/phusetube)
🌐 [/company/phuse](https://company.phuse.com)